Oligonucleotide Synthesis Market

Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligo (Primer), Reagents), Type (Custom, Predesigned), Application (Therapeutic (ASO, siRNA), Research ((PCR, Sequencing, Diagnostics)), End User (Pharma, CROS, CMOs) - Global Forecast to 2027

Report Code: BT 2680 Nov, 2022, by marketsandmarkets.com

[280 Pages Report] The global oligonucleotide synthesis market is projected to reach USD 16.7 billion by 2027 from USD 7.7 billion in 2022, at a CAGR of 16.8% during the forecast period. The major factor driving the growth of this market is the growing focus on personalized genome sequencing that helps determine the best approach for patient care, whether preventive, diagnostic, or therapeutic. Furthermore, increase in government-funded projects is also expected to positively impact the overall growth of the oligonucleotide synthesis market.

Attractive Opportunities in Oligonucleotide Synthesis Market

Oligonucleotide Synthesis Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global Oligonucleotide Synthesis Market Dynamics

Increasing government investments in synthetic biology and genome projects

In recent years, governments in various countries have made significant investments in synthetic biology and genomics projects. These government investments have played a major role in developing new technologies. For instance, the Li Ka Shing Foundation (Hongkong) donated USD 63 million to launch a synthetic biology research institute at the Hong Kong University of Science and Technology (HKUST) in 2019.

Complexities associated with therapeutic oligos

The importance of synthetic oligos as therapeutic drugs for treating diseases has grown significantly in the last decade. Therapeutic oligos are also useful in treating viral infections, respiratory diseases, cancer, and rare diseases such as Duchenne Muscular Dystrophy (DMD), cystic fibrosis, and thrombotic thrombocytopenic purpura. However, there have been various instances wherein many drugs have been withdrawn or failed in clinical trial phases due to complexities such as severe side effects. Such instances could become recurrent and restrain market growth to a certain extent.

Key players in emerging economies

Countries such as China, India, and Singapore and emerging economies such as Brazil provide significant growth opportunities for the oligonucleotide synthesis markets. This potential is mainly due to the increasing R&D investments by various companies in emerging economies of the Asia Pacific and Latin America regions. For instance, in 2020, IDT (US) opened IDT China, an official business entity in China, to better serve its customer base in the region, reach new customers, and provide easier access to its products, including custom DNA and RNA oligos, probes, and primers.

Delivery of oligonucleotide drugs to specific targets

Limitations of the present vector technologies have slowed the progress of gene therapy and antisense therapy for cancer in the clinic. Thus, the development of appropriate delivery systems for targeting therapeutic genes and antisense agents into targeted tumour cells and tissues is one of the potential approaches that have to be further explored in the future to expand gene therapy and antisense therapy against a wide range of cancers.

The oligonucleotide-based drugs segment accounted for the largest share in 2021:

In 2021, the oligonucleotide-based drugs segment held the largest share of the oligonucleotide synthesis market. This is because the oligonucleotide-based drugs, specifically antisense oligonucleotides, and interference RNA, are part of an increasing number of pharmaceutical and biotechnology programs for the treatment of numerous indications, including cancer, cardiovascular, neurodegenerative, neuromuscular, and respiratory diseases.

Oligonucleotide Synthesis Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for oligonucleotide synthesis market in 2021.

North America, comprising the US and Canada, is the largest regional segment in the oligonucleotide synthesis market. The North American market accounted for the largest share of the oligonucleotide synthesis market in 2021. According to the American Cancer Society (ACS), in 2020, the expected total number of new cancer cases diagnosed reached approximately 1,806,590, equivalent to approximately 4,950 new cases each day in the US. Considering the potential of therapeutic oligos in cancer diseases, the oligonucleotide synthesis market is expected to flourish in the coming years

Key Market Players

Key players in the market include Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), and Maravai Life Sciences (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

Product, Application, End User, and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, the Middle East & Africa

Companies covered

Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), Kaneka Corporation (Japan),  Biolegio B.V (Netherlands), Biolytic Lab Performance Inc. (US),  Microsynth AG (Switzerland), ATDBio Ltd. (UK), Twist Bioscience Corporation (US), Eton Bioscience, Inc. (US), CSBIO (US), Tag Copenhagen A/S (Denmark), Generi Biotech (Czech Republic), Biocomma Limited (China), Hongene Biotech Corporation (China), Hangzhou pharm &chem Co., Ltd (China), Tokyo Chemical Industry Co., Ltd. (Japan), Biogen Inc. (US), Sarepta Therapeutics, Inc. (US), Ionis Pharmaceuticals, Inc. (US), Alnylam Pharmaceuticals, Inc. (US)

This report categorizes the oligonucleotide synthesis market into the following segments and subsegments

By Product
  • Oligonucleotide-based Drugs
  • Synthesized Oligonucleotides
    • By Product
      • Primers
      • Probes
      • DNA Oligos
      • RNA Oligos
      • Other Synthesized Oligos
    • By Type
      • Customized Oligos
      • Predesigned Oligos
  • Reagents
  • Equipment  
By Application
  • Research Applications
  • Diagnostic Applications
  • Therapeutic Applications
    • By Type
      • Antisense Oligonucleotide-based Therapies 
      • siRNA Oligonucleotide-based Therapies
      • CpG Oligonucleotide-based Therapies
    •  By Disease Type
      • Neurological Disorders
      • Infectious Diseases
      • Other Diseases
By End User
  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • CROs and CMOs
  • Academic Research Institutes
By Region
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In 2020, Danaher Corporation (US) opened IDT China, an official business entity, to better serve its regional customer base, reach out to new customers, and provide easier access to its complete portfolio of industry-leading products.
  • In 2020, Danaher (US) acquired the Biopharma business from General Electric Company’s (US) Life Sciences division. It was renamed Cytiva and will act as a standalone operating company within Danaher’s Life Sciences segment. This acquisition strengthened Danaher’s position in the oligo synthesizer and reagents market.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Content

1 Introduction
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 INCLUSIONS & EXCLUSIONS
           1.3.3 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 Research Methodology 
    2.1 Research Data
           2.1.1 Secondary Sources
                    2.1.1.1 Key data from secondary sources
           2.1.2 Primary Sources
                    2.1.2.1  Key data from primary sources
    2.2 Market Size Estimation 
           2.1.1 Revenue Share Analysis
           2.1.2 Illustrative Figure of Revenue Share Analysis
    2.3 Market Breakdown And Data Triangulation
    2.4 Market Share Estimation
    2.5 Assumptions For The Study

3 Executive Summary 

4 Premium Insights 

5 Market Overview 
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
           5.2.2 Restraints
           5.2.3 Opportunities
           5.2.4 Challenges
    5.3 Market Trends
    5.4 Ranges/Scenario
    5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS/YC-YCC Shift
    5.6 Indicative Pricing Model Analysis 
    5.7 Value Chain Analysis
    5.8 Supply chain analysis
    5.9 Ecosystem Analysis
    5.10 Technology Analysis
    5.11 Patent analysis
    5.12 Key conferences & events in 2022-23
    5.13 Regulatory Landscape
    5.14 Regulatory bodies, government agencies and other organizations
    5.15 Porter's Five Forces Analysis
    5.16 Key stakeholders and buying criteria

6 Oligonucleotide synthesis Market, by product
    6.1 Introduction
    6.2 Oligonucleotide-based drugs
    6.3 Synthesized Oligonucleotides
           6.3.1 By Product
                    6.3.1.1 Primers
                    6.3.1.2 Probes
                    6.3.1.3 DNA Oligos
                    6.3.1.4 RNA Oligos
                    6.3.1.5 Other synthesized Oligos [Bridged nucleic acid (BNA), Locked nucleic acid (LNA)]
           6.3.2 By Type
                    6.3.2.1 Custom oligonucleotides
                    6.3.2.2 Predesigned oligos
    6.4 Reagents
    6.5 Equipment

7 Oligonucleotide synthesis Market, by application
    7.1 Introduction
    7.2 Therapeutic Applications
           7.2.1 By type
                    7.2.1.1 Antisense Oligonucleotide-based Therapies
                    7.2.1.2 siRNA Oligonucleotide-based Therapies
                    7.2.1.3 CpG Oligonucleotide-based Therapies
           7.2.2 By disease type
                    7.2.1.1 Neurological disorders
                    7.2.1.2 Infectious diseases
                    7.2.1.3 Other diseases (rare genetic diseases, cardiovascular diseases, cancer, inflammatory diseases, autoimmune disease)
    7.3 Diagnostic Applications
    7.4 Research Applications
           7.4.1 PCR
           7.4.2 Sequencing
           7.4.3 Other research applications (nucleic acid hybridization methods, microarrays, southern blotting methods)

8 Oligonucleotide synthesis Market, By End User
    8.1 Introduction
    8.2 Hospitals
    8.3 Pharmaceutical & Biotechnology companies
    8.4 Diagnostic Laboratories
    8.5 CROs & CMOs
    8.6 Academic Research Institutes

9 Oligonucleotide synthesis Market, By Region
    9.1 Introduction 
    9.2 North America 
           9.2.1 US
           9.2.2 Canada
    9.3 Europe 
           9.3.1 Germany
           9.3.2 France
           9.3.3 UK
           9.3.4 Italy
           9.3.5 Spain
           9.3.6 RoE
    9.4 Asia Pacific
           9.4.1 Japan
           9.4.2 China
           9.4.3 India
           9.4.6 RoAPAC
           9.5.1 Latin America
           9.5.2 Brazil
           9.5.3 Mexico
           9.5.4 RoLATAM
    9.6 Middle East Africa

10 Competitive Landscape
     10.1 Introduction 
     10.2 Key Player Strategies/Right to Win
     10.3 Revenue Analysis
     10.4 Market Share Analysis
     10.5 Company Evaluation Quadrant
             10.5.1 Stars
             10.5.2 Emerging Leaders
             10.5.3 Pervasive Players
             10.5.4 Emerging Companies
             10.5.5 Participants
     10.6 Company Evaluation Quadrant: Start-ups/SMEs
     16.7 Competitive Benchmarking 
             16.7.1 DETAILED LIST OF KEY STARTUP/SMES
             16.7.2 COMPETITIVE BENCHMARKING OF key players [startups/smes]
     10.7 Competitive Scenario and Trends

11 Company Profiles
     11.1 Key Market Players
             11.1.1 Danaher Corporation (US)
             11.1.2 Thermo Fisher Scientific Inc. (US)
             11.1.3 Merck KGaA (Germany)
             11.1.4 LGC Limited (UK)
             11.1.5 Maravai Life Sciences (US)
             11.1.6 Agilent Technologies, Inc. (US)
             11.1.7 Eurofins Scientific (Germany)
             11.1.8 Kaneka Corporation (Japan)
             11.1.9 Biolegio B.V (Netherlands)
             11.1.10 Biolytic Lab Performance Inc. (US)
             11.1.11 Microsynth AG (Switzerland)
                        11.1.11.1 Other Players
             11.1.12 ATDBio Ltd. (UK)
             11.1.13 Twist Bioscience Corporation (US)
             11.1.14 Eton Bioscience, Inc. (US)
             11.1.15 CSBIO (US)
             11.1.16 Tag Copenhagen A/S (Denmark)
             11.1.17 Generi Biotech (Czech Republic)
             11.1.18 Biocomma Limited (China)
             11.1.19 Hongene Biotech Corporation (China)
             11.1.20 Hangzhou pharm &chem Co., Ltd (China)
             11.1.21 Tokyo Chemical Industry Co., Ltd. (Japan)
                        11.1.21.1 Therapeutic Market Players
             11.2.1 Biogen Inc. (US)
             11.2.2 Sarepta Therapeutics, Inc. (US)
             11.2.3 Ionis Pharmaceuticals, Inc. (US)
             11.2.4 Alnylam Pharmaceuticals, Inc. (US)

12 Appendix
     12.1 Discussion guide
     12.2 Knowledge Store: MarketsandMarkets' Subscription Portal
     12.3 Available Customisations
     12.4 Related Reports
     12.5 Author Details

This study involved four major activities in estimating the current size of the oligonucleotide synthesis market. Exhaustive secondary research was conducted to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), Food and Drug Administration (FDA), National Center for Biotechnology Information (NCBI), Industry Association of Synthetic Biology (IASB), Biotechnology Innovation Organization (BIO), and Genome Canada. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information and assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Oligonucleotide Synthesis Market Size, and Share

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue. As of 2021, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the oligonucleotide synthesis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the oligonucleotide synthesis business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global oligonucleotide synthesis market based on the product, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oligonucleotide synthesis market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the oligonucleotide synthesis market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
Report Code
BT 2680
Published ON
Nov, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Synthesis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback